$Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival$
Código QR

Código QR

Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival

Guardado en:

Detalles Bibliográficos
Autores principales:	Hui Zheng, Eirini Pectasides, Mohamed Uduman, Charles S Fuchs, James M Cleary, Adam J Bass, Jérémy Augustin, Leonie K de Klerk, Anuj K Patel, Sarah Derks, Nihal Raman, Fahire G Akarca, Nadine J McCleary, Douglas A Rubinson, Jeffrey W Clark, Bridget Fitzpatrick, Lauren K Brais, Megan E Cavanaugh, Amanda J Rode, Melissa G Jean, Patrick H Lizotte, Matthew J Nazzaro, Peter C Enzinger
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/88b5dffda1124385a9d172a7073bce20
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Investigating the accuracy, risk impact, and cost-effectiveness of component-resolved diagnostic test for food allergy: a systematic review protocol
por: Javier Flores Kim, et al.
Publicado: (2017)

El poder y los valores en Weber, Freud y Kelsen, a la luz del "nuevo paradigma científico" y en relación con América Latina
por: Cleary,Eda
Publicado: (2011)

Hypertrophic lichenoid dermatitis during pembrolizumab treatment
por: Ryoma Honda, et al.
Publicado: (2021)

Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids May Extend above and below Pons and Is Associated with Other Autoimmune Diseases
por: Brent Berry, et al.
Publicado: (2021)

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer.
por: Christine S Walsh, et al.
Publicado: (2021)

Contemporary Islamism
por: Matthew Cleary, et al.
Publicado: (2007)

Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection
por: Alexa C. Glencer, et al.
Publicado: (2021)

Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma
por: S. C. Sasson, et al.
Publicado: (2021)

Comparative transcriptional profiling of canine acanthomatous ameloblastoma and homology with human ameloblastoma
por: Santiago Peralta, et al.
Publicado: (2021)

Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission
por: Richard Carvajal, et al.
Publicado: (2021)

Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma
por: Sanju Cyriac, et al.
Publicado: (2021)

Metastatic cervical cancer: clinical experience with pembrolizumab application. Case report
por: Anna E. Protasova, et al.
Publicado: (2021)

CT based radiomic approach on first line pembrolizumab in lung cancer
por: Marta Zerunian, et al.
Publicado: (2021)

Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer
por: Noguchi S, et al.
Publicado: (2020)

Shrinkage of a pituitary metastasis of melanoma induced by pembrolizumab: a case report
por: Giuseppe Giuffrida, et al.
Publicado: (2021)

The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
por: Lars Ny, et al.
Publicado: (2021)

Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity
por: S. Y. Cindy Yang, et al.
Publicado: (2021)

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
por: Tanya E. Keenan, et al.
Publicado: (2021)

Robust response of pulmonary pleomorphic carcinoma to pembrolizumab and sequential radiotherapy: A case report
por: Tae‐Hun Kim, et al.
Publicado: (2021)

Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
por: Somasundaram A, et al.
Publicado: (2017)

Quantitative description of the interactions among kinase cascades underlying long-term plasticity of Aplysia sensory neurons
por: Yili Zhang, et al.
Publicado: (2021)

A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma
por: Wu L, et al.
Publicado: (2021)

Pembrolizumab-Induced Lichen Planus on the Scalp of a Patient with Non-Small-Cell Lung Carcinoma
por: Aya Yamashita, et al.
Publicado: (2021)

Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study
por: Jean-Louis Pujol, MD, PhD, et al.
Publicado: (2021)

A multifaceted intervention to improve the quality of care of children in district hospitals in Kenya: a cost-effectiveness analysis.
por: Edwine W Barasa, et al.
Publicado: (2012)

Prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study
por: Satoru Taguchi, et al.
Publicado: (2021)

Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report
por: Kin-Sang Lau, et al.
Publicado: (2021)

Pathological Complete Response of Clinical T4b Ascending Colon Cancer after Preoperative Chemotherapy Using Pembrolizumab
por: Terufumi Yoshida, et al.
Publicado: (2021)

Durable Complete Response to Pembrolizumab in Esophageal Squamous Cell Carcinoma With Divergent Microsatellite Status: A Case Report
por: Tian Zeng, et al.
Publicado: (2021)

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
por: Antoni Ribas, et al.
Publicado: (2020)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
por: Qiao Liu, et al.
Publicado: (2021)

Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
por: Vamsidhar Velcheti, et al.
Publicado: (2021)

Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series
por: Kei Sonehara, et al.
Publicado: (2021)

Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial
por: Jeffrey A. How, et al.
Publicado: (2021)

Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer
por: Weinberg F, et al.
Publicado: (2019)

Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
por: Yuki Katsumata, et al.
Publicado: (2021)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer
por: Qiao Liu, et al.
Publicado: (2021)

Comparison of drug delivery with autoinjector versus manual prefilled syringe and between three different autoinjector devices administered in pig thigh
por: Hill RL, et al.
Publicado: (2016)

CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma
por: Jin Zhou, et al.
Publicado: (2017)

Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates
por: Mary L Disis, et al.
Publicado: (2021)